These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 29665987

  • 1. Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?
    Dijk W, Le May C, Cariou B.
    Trends Endocrinol Metab; 2018 Jun; 29(6):420-434. PubMed ID: 29665987
    [Abstract] [Full Text] [Related]

  • 2. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
    Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S.
    Circulation; 2014 Jul 29; 130(5):431-41. PubMed ID: 25070550
    [Abstract] [Full Text] [Related]

  • 3. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 4. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps.
    Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, Catapano AL, Bellosta S.
    Pharmacol Res; 2018 Apr 15; 130():1-11. PubMed ID: 29428206
    [Abstract] [Full Text] [Related]

  • 5. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3452-3460. PubMed ID: 28673045
    [Abstract] [Full Text] [Related]

  • 6. PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.
    Lagace TA.
    Curr Opin Lipidol; 2014 Oct 01; 25(5):387-93. PubMed ID: 25110901
    [Abstract] [Full Text] [Related]

  • 7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 01; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 8. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H, Rashid S, Fazio S.
    Atherosclerosis; 2015 Feb 01; 238(2):264-70. PubMed ID: 25544176
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 01; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 12. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD.
    Atherosclerosis; 2011 Jul 01; 217(1):263-7. PubMed ID: 21497351
    [Abstract] [Full Text] [Related]

  • 13. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C, Ruilope LM.
    Med Clin (Barc); 2015 Jul 20; 145(2):67-9. PubMed ID: 26004275
    [No Abstract] [Full Text] [Related]

  • 14. Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.
    Guo S, Xia XD, Gu HM, Zhang DW.
    Adv Exp Med Biol; 2020 Jul 20; 1276():137-156. PubMed ID: 32705598
    [Abstract] [Full Text] [Related]

  • 15. Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables.
    Filippatos TD, Kei A, Rizos CV, Elisaf MS.
    J Cardiovasc Pharmacol Ther; 2018 Jan 20; 23(1):3-12. PubMed ID: 28826253
    [Abstract] [Full Text] [Related]

  • 16. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2014 May 20; 47(7-8):679-82. PubMed ID: 24680982
    [Abstract] [Full Text] [Related]

  • 17. [The expression and clinical significance of proprotein convertase subtilisin kexin 9 in rheumatoid arthritis].
    Du Q, Yu XJ, Li HJ, Guan SQ, Zhang ZY, Mei YF.
    Zhonghua Nei Ke Za Zhi; 2017 Sep 01; 56(9):655-659. PubMed ID: 28870033
    [Abstract] [Full Text] [Related]

  • 18. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ, Li JJ.
    Clin Chim Acta; 2014 Apr 20; 431():148-53. PubMed ID: 24518357
    [Abstract] [Full Text] [Related]

  • 19. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan 20; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 20. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.
    Tavori H, Giunzioni I, Linton MF, Fazio S.
    Circ Res; 2013 Dec 06; 113(12):1290-5. PubMed ID: 24122718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.